However, there are increasing reports of sarcoidosis following treatment with IFN-α and IFN-β in different diseases, including hepatitis C, renal cell carcinoma, multiple myeloma, and multiple sclerosis (MS) [4]. This evidence concerns the gene IFNB1 and plasma cell myeloma.